Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 57 of 1,261
  1. US 12246014

    Azetidine derivatives

    Ligand UK Development Limited · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  2. US 12246059

    Stable hybrid FC fusion G-CSF formulation

    ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  3. US 12246011

    Radiation mitigator and method of use thereof

    The Board of Regents of the University of Oklahoma · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  4. US 12247037

    1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

    Neumora Therapeutics, Inc. · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  5. US 12246012

    Method for treating nervous system injuries using boldine and derivatives thereof

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 11, 2025 · Expires Mar 6, 2045

    granted
  6. WO 2025046413

    VECTEURS DE VIA DE VMN ET LEURS UTILISATIONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Mar 6, 2025 · Expires Mar 1, 2045

    granted
  7. WO 2025046414

    VECTEURS DE CDV VIA ET LEURS UTILISATIONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Mar 6, 2025 · Expires Mar 1, 2045

    granted
  8. WO 2025047847

    VARIANT DE RÉGION Fc

    ASTELLAS PHARMA INC [JP] · Granted Mar 6, 2025 · Expires Mar 1, 2045

    granted
  9. WO 2025049275

    INHIBITEURS DE LA PROTÉINE DE LIAISON À L'ÉMOPAMIL ET LEURS UTILISATIONS

    BIOGEN MA INC [US] · Granted Mar 6, 2025 · Expires Mar 1, 2045

    granted
  10. US 12239712

    Combination therapy for the treatment of liver disease

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  11. US 12239654

    Compounds and methods for treating neurological and cardiovascular conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  12. US 12240831

    Pyridazinone compounds and uses thereof

    EDGEWISE THERAPEUTICS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  13. US 12239694

    Methods and compositions for improved cognition

    The Regents of the University of California · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  14. US 12240907

    N-terminal scFv multispecific binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  15. US 12239656

    Nucleoporins as drug targets for anti-proliferative therapeutics

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  16. US 12241067

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  17. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  18. US 12239677

    Therapeutic bacteriophage compositions for treating Staphylococcus infection

    Armata Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  19. US 12239684

    Modulators of complement activity

    RA PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  20. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Soricimed Biopharma Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  21. US 12239709

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  22. US 12240816

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  23. US 12239716

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  24. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    MAB-LEGEND BIOTECH CO., LTD. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.